Cargando…

Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK

OBJECTIVE: With healthcare systems under increasing financial pressure from costs associated with diabetes care, it is important to assess which treatments provide clinical benefits and represent best value. This study evaluated the annual costs of insulin degludec (degludec) versus insulin detemir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thalange, Nandu, Gundgaard, Jens, Parekh, Witesh, Tutkunkardas, Deniz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Clinical care education/Nutrition
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731813/ https://www.ncbi.nlm.nih.gov/pubmed/31543973 http://dx.doi.org/10.1136/bmjdrc-2019-000664

Ejemplares similares

The rate of hyperglycemia and ketosis with insulin degludec‐based treatment compared with insulin detemir in pediatric patients with type 1 diabetes: An analysis of data from two randomized trials
por: Thalange, Nandu, et al.
Publicado: (2019)

DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal–Bolus Regimens for Type 2 Diabetes in the UK
por: Pollock, Richard F., et al.
Publicado: (2018)

Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)
por: Pollock, Richard F., et al.
Publicado: (2019)

Development of Insulin Detemir/Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2–16 Years
por: Thalange, Nandu, et al.
Publicado: (2016)

Comparing the efficacy and safety of insulin detemir versus neutral protamine hagedorn insulin in treatment of diabetes during pregnancy: a randomized, controlled study
por: ji, Jing, et al.
Publicado: (2020)

Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting
por: Evans, Marc, et al.
Publicado: (2018)

Comparison of Once- Versus Twice-Daily Administration of Insulin Detemir, Used With Mealtime Insulin Aspart, in Basal-Bolus Therapy for Type 1 Diabetes: Assessment of Detemir Administration in a Progressive Treat-To-Target Trial (ADAPT)
por: Le Floch, Jean-Pierre, et al.
Publicado: (2009)

Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus
por: Evans, Marc, et al.
Publicado: (2017)

Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes
por: Thalange, Nandu, et al.
Publicado: (2015)

Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective
por: Evans, Marc, et al.
Publicado: (2016)

Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus
por: Kusunoki, Yoshiki, et al.
Publicado: (2013)

Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial
por: Evans, Marc, et al.
Publicado: (2020)

Healthcare Resource Utilization and Costs Associated with Ketosis Events in Pediatric and Adult Patients with Type 1 Diabetes Mellitus in the UK
por: Thalange, Nandu, et al.
Publicado: (2017)

A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9)
por: Lane, Wendy S., et al.
Publicado: (2020)

Clinical Use of Degludec in Children and Adolescents with T1D: A Narrative Review with Fictionalized Case Reports
por: Thalange, Nandu, et al.
Publicado: (2019)

Preference for high-carbohydrate foods does not change for children and adolescents in insulin-induced hypoglycemia
por: Sauchelli, Sarah, et al.
Publicado: (2022)

Short‐term cost‐utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9)
por: Pollock, Richard F., et al.
Publicado: (2019)

The value of fast-acting insulin aspart compared with insulin aspart for patients with diabetes mellitus treated with bolus insulin from a UK health care system perspective
por: Leelarathna, Lalantha, et al.
Publicado: (2018)

A 1‐year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal–bolus insulin therapy (Kumamoto Insulin Degludec Observational study)
por: Shimoda, Seiya, et al.
Publicado: (2016)

Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience
por: Kalra, Sanjay
Publicado: (2016)

100 years on: the impact of the discovery of insulin on clinical outcomes
por: Buse, John B, et al.
Publicado: (2021)

Impact of concomitant oral glucose-lowering medications on the success of basal insulin titration in insulin-naïve patients with type 2 diabetes: a systematic analysis
por: Wollenhaupt, Dominik, et al.
Publicado: (2023)

Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes
por: Kotwal, Anupam, et al.
Publicado: (2019)

Comparison of Glycemic Variability Associated With Insulin Glargine and Intermediate-Acting Insulin When Used as the Basal Component of Multiple Daily Injections for Adolescents With Type 1 Diabetes
por: White, Neil H., et al.
Publicado: (2009)

Insulin use and new diabetes after acceptance for bariatric surgery: comparison of outcomes after completion of surgery or withdrawal from the program
por: Lee, Jessica H, et al.
Publicado: (2020)

Determining starting basal rates of insulin infusion for insulin pump users: a comparison between methods
por: Chow, Nelson, et al.
Publicado: (2016)

In vivo investigation of the tissue response to commercial Teflon insulin infusion sets in large swine for 14 days: the effect of angle of insertion on tissue histology and insulin spread within the subcutaneous tissue
por: Eisler, Gabriella, et al.
Publicado: (2019)

Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany
por: Pscherer, Stefan, et al.
Publicado: (2010)

Degludec insulin: A novel basal insulin
por: Kalra, Sanjay, et al.
Publicado: (2011)

Trends in glycemic control in patients with insulin therapy compared with non-insulin or no drugs in type 2 diabetes in Japan: a long-term view of real-world treatment between 2002 and 2018 (JDDM 66)
por: Yokoyama, Hiroki, et al.
Publicado: (2022)

Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol
por: Davis, Sondra, et al.
Publicado: (2017)

The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin
por: Cengiz, Eda, et al.
Publicado: (2012)

Carbohydrate-last meal pattern lowers postprandial glucose and insulin excursions in type 2 diabetes
por: Shukla, Alpana P, et al.
Publicado: (2017)

Mealtime insulin BOLUS score increases prior to clinic visits in youth with type 1 diabetes
por: McConville, Andrew, et al.
Publicado: (2020)

Key factors for overcoming psychological insulin resistance: an examination of patient perspectives through content analysis
por: Stuckey, Heather, et al.
Publicado: (2019)

Comparison of the Efficacy and Safety of Insulin Glargine and Insulin Detemir with NPH Insulin in Children and Adolescents with Type 1 Diabetes Mellitus Receiving Intensive Insulin Therapy
por: Dündar, Bumin Nuri, et al.
Publicado: (2009)

Weight‐sparing effect of insulin detemir: a consequence of central nervous system‐mediated reduced energy intake?
por: Russell‐Jones, D., et al.
Publicado: (2015)

Development and validation of a prediction model for insulin-associated hypoglycemia in non-critically ill hospitalized adults
por: Mathioudakis, Nestoras Nicolas, et al.
Publicado: (2018)

Cord serum metabolome and birth weight in patients with gestational diabetes treated with metformin, insulin, or diet alone
por: Huhtala, Mikael S, et al.
Publicado: (2021)

Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension
por: Mathieu, Chantal, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_gaku4pifil3u60a8309ahrlleo